CN105153131A - Medicine combination for treating human neuroglioma during nursing - Google Patents
Medicine combination for treating human neuroglioma during nursing Download PDFInfo
- Publication number
- CN105153131A CN105153131A CN201510603092.7A CN201510603092A CN105153131A CN 105153131 A CN105153131 A CN 105153131A CN 201510603092 A CN201510603092 A CN 201510603092A CN 105153131 A CN105153131 A CN 105153131A
- Authority
- CN
- China
- Prior art keywords
- compound
- human glioma
- pharmaceutical composition
- nursing
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
Abstract
The invention relates to a medicine combination for treating human neuroglioma during nursing. The medicine combination comprises an effective quantity of compound and a pharmaceutically acceptable carrier, and the compound is of a structure in the specification. The compound of the medicine combination has growth inhibition activity on human neuroglioma cells.
Description
Technical field
The present invention relates to field of medicaments, relate in particular to a kind of pharmaceutical composition for the treatment of human glioma in nursing.
Background technology
Neurospongioma is also known as glioma, betide neuroectodermal various tumour, the most common in the various tumours of encephalic, due to the anatomic characteristic of neural system and head, neurospongioma seldom transfers to its hetero-organization by vascular system, and majority is Brain metastases.
At present, operation is comprised to the treatment means of neuroglial cytoma, radiotherapy etc., but general curative effect is still undesirable, after being organized by ocal resection, the high transitivity neuroglial cytoma had even can transfer to other organs at a distance by vascular system, but the neuroglial cytoma of these transfers is usually to radiotherapy, chemotherapy etc. are insensitive, are thus difficult to be uprooted, existing during hidden danger.Therefore, need clinically to continually develop new effective medicine.
Summary of the invention
The object of this invention is to provide a kind of pharmaceutical composition for the treatment of human glioma in nursing.
In order to realize object of the present invention, the invention provides a kind of compound for the treatment of human glioma in nursing, this compound has having structure:
The present invention also provides a kind of pharmaceutical composition for the treatment of human glioma in nursing, and described pharmaceutical composition includes the compound of effective amount and pharmaceutically acceptable carrier, and described compound has having structure:
Preferably, described pharmaceutically acceptable carrier is thinner, disintegrating agent, tackiness agent, lubricant, stablizer or corrigent.
Preferably, described thinner is sugar derivatives, starch derivative or derivatived cellulose.
Preferably, described thinner is lactose.
Preferably, described pharmaceutical composition is powder, microgranules, granule, capsule or tablet.
The present invention also provides compound being prepared in the purposes of nursing treating in the medicine of human glioma, and this compound has having structure:
The present invention also provides the purposes of compound in the medicine of preparation vitro inhibition human glioma cell U87 growth activity, and this compound has having structure:
Term used herein " pharmaceutically acceptable " refers to not eliminate the biologic activity of compound as herein described or the material of character, as carrier or thinner.This kind of material is applied to and individual does not cause undesirable biological action or not with harmful way and any component interaction comprised in its composition.
" pharmaceutically acceptable carrier " comprises any and all solvents as the term is employed herein, dispersion medium, coating material, tensio-active agent, antioxidant, sanitas (such as antiseptic-germicide, anti-mycotic agent), isotonic agent, absorption delay agent, salt, sanitas, drug stabilizing agent, tackiness agent, vehicle, disintegrating agent, lubricant, sweeting agent, correctives, dyestuff etc. and its combination, this is well-known to those skilled in the art (for example, see Remington'sPharmaceuticalSciences, 18thEd.MackPrintingCompany, 1990, pp.1289-1329).Except with except the inconsistent carrier of activeconstituents, consider to use any conventional carrier in treatment or pharmaceutical composition.
Compound of the present invention has growth inhibitory activity to human glioma cell.
Embodiment
The present invention is further illustrated below by embodiment.It should be understood that embodiments of the invention are for illustration of the present invention instead of limitation of the present invention.Essence according to the present invention all belongs to the scope of protection of present invention to the simple modifications that the present invention carries out.Unless otherwise stated, the percentage ratio in the present invention is weight percentage.
The research of the purposes of experimental example the compounds of this invention in the medicine of preparation vitro inhibition human glioma cell U87 growth activity
In the present invention, compound has having structure:
Test principle
Mtt assay (tetramethyl-azo azoles salt trace enzyme reaction colorimetry) is to analyze based on metabolism reduction tetramethyl-azo azoles salt.In vitro under environment, the MTT of yellow, by the effect of desaturase in mitochondrial process, is reduced to insoluble hepatic formazan by viable cell, and in dead cell, this enzyme disappears, and MTT is not reduced.Therefore, the affected situation of tumour cell (Tan Weidong, golden red can be reflected by measuring the change of the solution colour depth, Luo Dixiang, Deng. the comparison [J] of mtt assay and srb assay in screening anti-tumor medicine. research and development of natural products, 1999,11 (3): 17-22.).Mtt assay is easy and simple to handle, responsive, repeatable and S-N ratio is good.
Cell cultures
Human glioma cell (the U87 taken the logarithm vegetative period, purchased from abundant bio tech ltd of upper Hisense), to include RPMI-1640 nutrient solution (purchased from the Shanghai Ken Qiang Instrument Ltd.) dilution of 10% (v/v) foetal calf serum (fetalbovineserum) for 5 × 10
4the cell suspending liquid of individual/L, is inoculated in 96 orifice plates, 100 μ L/ holes, be placed in 37 DEG C, saturated humidity, 5%CO
224h is cultivated in incubator.
After the compounds of this invention is dissolved with DMSO, by RPMI-1640 nutrient solution (purchased from Shanghai Ken Qiang Instrument Ltd.) 100,80,60,40,20,10 μ g/ml six gradient containing 10% (v/v) foetal calf serum.Above-mentioned pastille nutrient solution is added in 96 orifice plates, be positioned over the incubator of cell cultures the same terms in cultivate 48h, using as administration group.To add with the physiological saline person measured as a control group.Then add MTT to dye 4 hours, adopt microplate reader to measure OD value under 570nm.Data analysis calculates in accordance with the following methods: inhibitory rate of cell growth=[1-administration group OD value/control group OD value] × 100%
Result
For U87, the inhibitory rate of cell growth of 100,80,60,40,20,10 μ g/ml six gradients is respectively 55.6%, 47.5%, 41.9%, 36.2%, 33.1% and 30.1%.Experimental result shows, the compounds of this invention is external has growth inhibiting for human glioma cell U87, and toxicity test shows that toxicity is less, is applicable to continual exploitation to prepare new medicine.
Claims (8)
1. in nursing, treat a human glioma's compound, it is characterized in that, this compound has having structure:
2. in nursing, treat a human glioma's pharmaceutical composition, it is characterized in that, described pharmaceutical composition includes the compound of effective amount and pharmaceutically acceptable carrier, and described compound has having structure:
3. pharmaceutical composition for the treatment of human glioma in nursing according to claim 2, it is characterized in that, described pharmaceutically acceptable carrier is thinner, disintegrating agent, tackiness agent, lubricant, stablizer or corrigent.
4. pharmaceutical composition for the treatment of human glioma in nursing according to claim 3, it is characterized in that, described thinner is sugar derivatives, starch derivative or derivatived cellulose.
5. pharmaceutical composition for the treatment of human glioma in nursing according to claim 4, it is characterized in that, described thinner is lactose.
6. pharmaceutical composition for the treatment of human glioma in nursing according to claim 3, it is characterized in that, described pharmaceutical composition is powder, microgranules, granule, capsule or tablet.
7. compound is being prepared in the purposes of nursing treating in the medicine of human glioma, and it is characterized in that, this compound has having structure:
8. the purposes of compound in the medicine of preparation vitro inhibition human glioma cell U87 growth activity, it is characterized in that, this compound has having structure:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510603092.7A CN105153131B (en) | 2015-09-21 | 2015-09-21 | A kind of pharmaceutical composition that human glioma is treated in nursing |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510603092.7A CN105153131B (en) | 2015-09-21 | 2015-09-21 | A kind of pharmaceutical composition that human glioma is treated in nursing |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105153131A true CN105153131A (en) | 2015-12-16 |
| CN105153131B CN105153131B (en) | 2017-10-17 |
Family
ID=54794222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510603092.7A Expired - Fee Related CN105153131B (en) | 2015-09-21 | 2015-09-21 | A kind of pharmaceutical composition that human glioma is treated in nursing |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105153131B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105348270A (en) * | 2015-11-09 | 2016-02-24 | 吕显艳 | Medicine composition preventing dental body and dental pulp infection |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008047224A1 (en) * | 2006-10-19 | 2008-04-24 | Pfizer Limited | Pyrazolyl-4-oxy-benzonitrile derivatives useful in treating endometriosis |
| WO2009122180A1 (en) * | 2008-04-02 | 2009-10-08 | Medical Research Council | Pyrimidine derivatives capable of inhibiting one or more kinases |
| WO2015113452A1 (en) * | 2014-01-29 | 2015-08-06 | Glaxosmithkline Intellectual Property Development Limited | Compounds |
-
2015
- 2015-09-21 CN CN201510603092.7A patent/CN105153131B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008047224A1 (en) * | 2006-10-19 | 2008-04-24 | Pfizer Limited | Pyrazolyl-4-oxy-benzonitrile derivatives useful in treating endometriosis |
| WO2009122180A1 (en) * | 2008-04-02 | 2009-10-08 | Medical Research Council | Pyrimidine derivatives capable of inhibiting one or more kinases |
| WO2015113452A1 (en) * | 2014-01-29 | 2015-08-06 | Glaxosmithkline Intellectual Property Development Limited | Compounds |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105348270A (en) * | 2015-11-09 | 2016-02-24 | 吕显艳 | Medicine composition preventing dental body and dental pulp infection |
| CN105348270B (en) * | 2015-11-09 | 2018-01-09 | 吕显艳 | A kind of pharmaceutical composition for preventing and treating tooth body infections of dental pulp |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105153131B (en) | 2017-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108358973A (en) | Naphthalimide tetravalence platinum-like compounds, preparation method and its application in preparation of anti-tumor drugs | |
| US20220218605A1 (en) | Bifunctional nucleoside hydrogel, preparation method therefor and use thereof | |
| CN106336438B (en) | A kind of succinyl ononin and its application in terms of preparing cardiovascular disease medicine | |
| CN106344592A (en) | Application of mannuronic acid oligose with carboxyl at 1-position of reducing end and derivative to treatment of Parkinson's disease | |
| CN104398526B (en) | The application of triptolide and Celastrol in antineoplastic is prepared | |
| CN105153131A (en) | Medicine combination for treating human neuroglioma during nursing | |
| CN105213366B (en) | The medical usage and its pharmaceutical composition of gamboge ketone compound | |
| CN109793727A (en) | A kind of pharmaceutical composition and its application of effective anti-malignant tumor | |
| CN109985060A (en) | Dendrobium polysaccharide is in preparation prevention or restores to apply in the drug of Reproductive Damage after chemotherapy | |
| CN104987356A (en) | Ursolic acid-glycolysis inhibitor DCA conjugate and application thereof | |
| Xia et al. | An efficient cocrystallization strategy for separation of dihydromyricetin from vine tea and enhanced its antibacterial activity for food preserving application | |
| CN102379868A (en) | Antitumor medicament containing glycolysis inhibitor and preparation method and application of antitumor medicament | |
| CN107753483A (en) | Medicine and its application with meronecrosis inhibitory activity | |
| CN104926804A (en) | Compounds with anti-tumor effect, and preparation method and application of compounds | |
| CN108096273A (en) | The application of Glucose sulfate aldehydic acid oligosaccharides | |
| CN104382965A (en) | Anti-tumor medicament composition | |
| CN102276625B (en) | Thiadiazole derivative | |
| CN109223762A (en) | Glabrene is preparing the application in anticancer drug | |
| CN109350620B (en) | A kind of drug and application thereof for treating oophoroma | |
| CN110872273B (en) | Naphthalimide benzimidazole compound and application thereof | |
| CN102276626B (en) | Isoxazole-containing compound | |
| CN109602737B (en) | Application of hydroxysafflor yellow B in preparation of medicine for treating gastric cancer and medicine | |
| CN105218444A (en) | A kind of pharmaceutical composition for the treatment of lung cancer | |
| CN117462548A (en) | Application of camptothecine derivatives in preparation of medicines for treating bladder cancer | |
| CN104873547B (en) | A kind of pharmaceutical composition and preparation and purposes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20171017 Termination date: 20180921 |